Artificial heart maker CARMAT gets regulatory approvals to resume sales

[October 25, 2022]  PARIS (Reuters) - French medical devices company CARMAT said it had received the necessary regulatory approvals to resume commercial implants of its Aeson artificial hearts product and would resume sales soon.

"We will be resuming implants very soon and moving forward at a measured pace as we continue building our inventory of implantable prostheses, and ensure all patients are suitably monitored," Chief Executive Stéphane Piat said in a statement.

Chief Executive Officer of French artificial heart manufacturer Carmat, Stephane Piat, poses holding an artificial heart during an interview with Reuters in Velizy, near Paris, January 11, 2021. REUTERS/Christian Hartmann/File Photo

(Reporting by Sudip Kar-Gupta; Editing by Clarence Fernandez)

[© 2022 Thomson Reuters. All rights reserved.]  This material may not be published, broadcast, rewritten or redistributed.  Thompson Reuters is solely responsible for this content.